Alnylam Pharmaceuticals
ALNY
#601
Rank
S$44.30 B
Marketcap
$343.47
Share price
4.37%
Change (1 day)
37.33%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -S$0.25 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are S$2.09 Billion. In 2023 the company made an earning of -S$0.43 Billion, an increase over its 2022 earnings that were of -S$1.33 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -S$0.25 Billion-42.94%
2023 -S$0.43 Billion-67.84%
2022 -S$1.33 Billion36.93%
2021 -S$0.98 Billion-8.04%
2020 -S$1.06 Billion-15.66%
2019 -S$1.26 Billion12.23%
2018 -S$1.12 Billion62.91%
2017 -S$0.69 Billion17.78%
2016 -S$0.59 Billion43.44%
2015 -S$0.41 Billion60.69%
2014 -S$0.26 Billion98.2%
2013 -S$0.13 Billion
2011 -S$75.02 Million27.48%
2010 -S$58.85 Million-10.92%
2009 -S$66.06 Million95.77%
2008 -S$33.75 Million
2006 -S$54.06 Million-9.13%
2005 -S$59.49 Million34.74%
2004 -S$44.15 Million36.79%
2003 -S$32.28 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-S$0.8 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
S$6.79 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.17 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$0.17 Billion-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$56.61 Million-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
S$17.42 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
S$10.13 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
S$0.57 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel